Superworth

Estrella Immunopharma price to book ratio ESLA

Market value divided by the book value of the company's net assets, since 2023.

Today, Nov 2, 2026
n/m
not a meaningful number
Last meaningful
200×
Apr 2025
Peer median
1.8×

Estrella Immunopharma's price to book ratio is not a meaningful number today: shareholders' equity was zero, negative or not reported, so price to book does not exist.

It was last meaningful in Apr 2025, at 200×.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2025200×44.6×200×
202461.6×3.8×61.6×
20233.9×3.9×5.1×

Against its peers

Companies in Healthcare nearest Estrella Immunopharma's size, closest first, today.

CompanyPrice to book ratio
ESLAEstrella Immunopharman/m
NEPHNephros2.9×
ATNMActinium Pharmaceuticals1.5×
APTAlpha Pro Tech0.9×
SPROSpero Therapeutics1.4×
LFVNLifevantage2.2×
ICCCImmucell3.1×
KEQUKewaunee Scientific1.3×
PDEXPro DEX3.7×
Peer median1.8×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Estrella Immunopharma

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.